Cholestatic pruritus in patients with Alagille syndrome (ALGS) Advocacy Hub | UniteRare

At a Glance

Live from database

💊

2FDA treatments

💰

2Open funds

Regulatory Watchboard

3 events

Jun 2023Bylvay: FDA approved

treatment of cholestatic pruritus in patients 12 months of age and older with Alagille syndrome (ALGS)

FDAcompleted

Sep 2021Livmarli: FDA approved

Treatment of cholestatic pruritus in patients with Alagille syndrome (ALGS) 1 year of age and older

FDAcompleted

Aug 2012

Technetium Tc99m Sulfur Colloi: FDA approved

Localization of lymph nodes draining a primary tumor in patients with melanoma when used with a hand-held gamma counter

FDAcompleted

Data from FDA regulatory filings and ClinicalTrials.gov. Updated periodically.

Financial Assistance

2 programs

FINANCIAL LANDSCAPE SUMMARY

Total programs

Open now

Copay cards

Copay Assistance1

Technetium Tc99m Sulfur Colloi

Pharmalucence, Inc.

OpenContact for details

Patient Assistance Programs1

Bylvay

Ipsen Biopharmaceuticals, Inc.

OpenContact for detailsApply ↗

View all support programs on disease page →

Approved Treatments

2 FDA-approved

Bylvay

(ODEVIXIBAT)Orphan drug

Ipsen Biopharmaceuticals, Inc.

Ileal Bile Acid Transporter Inhibitor [EPC]

12.1 Mechanism of Action Odevixibat is a reversible inhibitor of the ileal bile acid transporter (IBAT). It decreases the reabsorption of bile acids (...

Approved Jun 2023FDA label ↗

Livmarli

(MARALIXIBAT CHLORIDE)Orphan drug

Mirum Pharmaceuticals Inc.

12.1 Mechanism of Action Maralixibat is a reversible inhibitor of the ileal bile acid transporter (IBAT). It decreases the reabsorption of bile acids ...

Approved Sep 2021FDA label ↗

View full treatment details on disease page →